Feist-Weiller Cancer Center Logo  
Home | Maps & Directions | About Us | Contact | How to Help
Search:    Submit Search
July 31, 2014 - 12:15am | 77°F
Patient Care | Clinical Studies | Scientific Research | Education | For Professionals | Support & Resources | Treatment at FWCC | Cancer Survivorship
Patient Care
Clinical Studies
Scientific Research
For Professionals
FWCC Giving Opportunities
eNewsletter Signup

FWCC and Caris Life Sciences Partner to Create Tumor DNA Database

clientuploads/Genomic Testing Photos/tumor-profiling.jpgDoctors at the LSU Health Shreveport Feist-Weiller Cancer Center will now have access to next-generation technology that determines the unique biological characteristics of each individual patient’s cancer tumor and identifies tailored chemotherapy or radiation regimens to attack it. The new capability is the result of emerging technology called tumor profiling. Feist-Weiller will partner with Caris Life Sciences of Irving, TX to offer the breakthrough technology to cancer patients of University Health Shreveport, a clinical partner of the LSU Health Shreveport School of Medicine.  The cancer center is the only one in a 250-mile radius to offer the advanced capability.

The region’s first clinical molecular profiling program will use Caris’ industry leading comprehensive tumor profiling service. The next-generation technology, called Caris Molecular Intelligence TM, will enhance the clinical and research expertise of Feist-Weiller Cancer Center. It will expand the center’s personalized medicine approach to care and offer more precise treatment planning for patients.

In recent years, molecular profiling has become a valuable tool for oncologists when making treatment decisions for patients with difficult-to-treat and/or rare and aggressive cancers. Caris Molecular Intelligence correlates the molecular data from a tumor with biomarker/drug associations from the latest clinical and scientific literature on cancer. This information is used to recommend therapies more or less likely to benefit the patient. It will also identify potential clinical trials for the patient. The system uses traditional pathology analysis methods, along with more-recently developed DNA sequencing technologies.

The partnership with Caris includes clinical support, patient and physician education and system integration.  It also creates a forum to pursue joint research opportunities.

For more information on the partnership with Caris Life Sciences, click here.



Dr. Cherie-Ann Nathan's Grant for Gumclientuploads/_photos/Dr Nathan small-1.jpg

Dr. Cherie-Ann Nathan, Professor & Chair of Otolaryngology and Head & Neck Surgery at the School of Medicine in Shreveport is a leading member of Feist-Weiller Cancer Center’s translational cancer care team, and her research involving curcumin received a $40,000 in-house Idea Grant which resulted in a $342,410 NCI grant.  

Now, Dr. Nathan has been awarded an additional $50,000 in grant funding from the LSU System’s Leveraging Innovation for Technology Transfer Program (LIFT2).  The grant will be used to develop a cancer-preventing chewing gum based off of her research on Curcumin, and its efficacy in preventing cancer.

Learn more about Dr. Nathan's research by clicking here 


Feist-Weiller Cancer Center 1501 Kings Highway Shreveport, LA 71103
Privacy Policy
LSU Health Shreveport is an equal opportunity affirmative action institution.
2009-2015 LSU Health Shreveport
Search | Feist-Weiller Home | Contact | Sitemap
| LSU Health Shreveport Home | Email | Webmaster